Zhengye Biotechnology Forms Joint Venture to Expand Poultry Vaccine Sales

The latest announcement is out from Zhengye Biotechnology Holding Ltd. ( (ZYBT) ).

On March 28, 2025, Zhengye Biotechnology Holding Ltd.’s operating entity, Jilin Zhengye Biological Products Co., Ltd., entered into a capital contribution agreement with Youjia Technology Consulting Service to form a new company, Zhongnong Zhengye Biological Technology (Beijing) Co., Ltd. This joint venture will focus on the sales of poultry vaccines manufactured by Jilin Zhengye, with a registered capital of RMB3,000,000. Jilin Zhengye will hold a 51% stake, while Youjia will hold 49%. This strategic move is expected to enhance Zhengye’s market presence in the biotechnology sector, particularly in the poultry vaccine market, and could potentially strengthen its operational capabilities and stakeholder value.

More about Zhengye Biotechnology Holding Ltd.

Zhengye Biotechnology Holding Ltd. operates in the biotechnology industry, focusing on the production and sale of biological products such as poultry vaccines. The company is based in Jilin Province, China, and aims to leverage its expertise in biotechnology to serve the agricultural sector.

YTD Price Performance: 2.06%

Average Trading Volume: 222,379

See more data about ZYBT stock on TipRanks’ Stock Analysis page.